Core Insights - The company reported total product revenue exceeding RMB 5.2 billion for the first half of the year, maintaining a strong growth rate of over 35% year-on-year [1] - In Q2 2025, total product revenue surpassed RMB 2.7 billion, with a year-on-year growth of over 30%, driven by both oncology and comprehensive pipelines [1] Oncology and Comprehensive Pipeline - The oncology treatment sector continues to show strong performance with leading brands and product combinations, while new product revenue contributions are steadily increasing [1] - The comprehensive product line is gradually releasing its potential, with new drivers of growth coming from products like Xinbile® (Tolebrutinib injection) and Xinbimin® (Tremelimumab N01 injection), which are making progress in marketing and channel access [1] - The approval of the world's first glucagon/GLP-1 dual receptor agonist, Xinermai® (Masitide injection), for weight loss indications by the National Medical Products Administration of China adds a significant product to the company's comprehensive pipeline [1] Product Approvals and Clinical Research - The company has successfully obtained approvals for 16 products, with 2 additional products under review by the National Medical Products Administration of China [1] - Four new drug molecules are currently in Phase 3 or pivotal clinical studies, and approximately 15 new drug candidates have entered clinical research [1]

Core Insights - The company reported total product revenue exceeding RMB 5.2 billion for the first half of the year, reflecting a strong growth of over 35% year-on-year [1] - In Q2 2025, total product revenue surpassed RMB 2.7 billion, with a year-on-year growth of over 30%, driven by both oncology and comprehensive pipelines [1] Oncology and Comprehensive Pipeline - The oncology treatment sector continues to show strong performance with leading brands and product combinations, while new product revenue contributions are on the rise [1] - The comprehensive product line is gradually releasing its potential, with new growth drivers from products like Xinbile® (Tolebrutinib injection) and Xinbimin® (Tremelimumab N01 injection), which are making progress in marketing and channel access [1] - The approval of the world's first dual receptor agonist for glucagon/GLP-1, Xinermai® (Masitide injection), for weight loss indication by the National Medical Products Administration of China adds a significant product to the company's comprehensive pipeline [1] Product Approvals and Clinical Research - The company has successfully obtained approvals for 16 products, with 2 additional products under review by the National Medical Products Administration of China [1] - Four new drug molecules are currently in Phase 3 or pivotal clinical studies, and approximately 15 new drug candidates have entered clinical research [1]

Core Insights - The company, Sinopharm (01801.HK), reported that its total product revenue exceeded 5.2 billion yuan in the first half of 2025, representing a year-on-year growth of over 35% [1] - In the second quarter, the total product revenue surpassed 2.7 billion yuan, with a year-on-year increase of over 30% [1] - The sustained growth in the second quarter is attributed to the dual drivers of oncology and comprehensive pipeline development [1]

（文章来源：第一财经） 信达生物在港交所发布公告，上半年总产品收入超52亿元，同比增超35%；第二季度产品收入超27亿 元，同比增长超30%。 ...

Group 1 - The company reported total product revenue exceeding RMB 5.2 billion in the first half of 2025, maintaining a strong growth of over 35% year-on-year [1] - In Q2 2025, total product revenue surpassed RMB 2.7 billion, with a year-on-year growth of over 30%, driven by both oncology and comprehensive product lines [1] - The growth in the oncology treatment sector is attributed to a strong brand and product portfolio, with major products showing excellent growth and new product contributions increasing [1] Group 2 - The company is focused on sustainable growth and global innovation, with a rich pipeline in oncology and comprehensive product lines (cardiovascular and metabolic, autoimmune, and ophthalmology) [2] - As of now, the company has obtained approval for 16 products, with 2 under review by the National Medical Products Administration of China, and 4 new drug molecules in Phase 3 or pivotal clinical studies [2] - The year 2025 marks an important period for the company as it aims to become an internationally leading biopharmaceutical company [2]

公司致力于可持续成长与全球创新两大战略，布局了肿瘤与综合产品线(心血管及代谢、自身免疫及眼 科)的丰厚管线。截至目前，公司已取得16款产品获批上市，2个品种在中国国家药品监督管理局审评 中，4个新药分子进入3期或关键性临床研究，另外约15个新药品种已进入临床研究。2025年是公司迈入 双轮驱动和全球创新发展新时期的重要一年，将朝着「成为国际一流的生物制药公司」的愿景稳步迈 进。 格隆汇8月7日丨信达生物(01801.HK)公布，于2025年上半年，公司共取得总产品收入超人民币52亿元， 同比保持35%以上的强劲增长；其中2025年第二季度总产品收入超过人民币27亿元，同比增长超过 30%。该季度的持续增长得益于肿瘤和综合管线双轮驱动共同发力：1)肿瘤治疗领域的领导品牌和产品 组合强大，主要产品保持优异增长，新产品收入贡献持续提升；及2)综合产品线潜力逐渐释放，贡献增 长新驱动力：信必乐®(托莱西单抗注射液)和信必敏®(替妥尤单抗N01注射液)市场营销和渠道准入工作 顺利推进，产品持续放量。于季度末，全球首个胰高血糖素╱胰高血糖素样肽-1(GCG/GLP-1)双受体激 动药物信尔美®(玛仕度肽注射液)的减重适应 ...

公司致力于可持续成长与全球创新两大战略，布局了肿瘤与综合产品线(心血管及代谢、自身免疫及眼 科)的丰厚管线。截至目前，公司已取得16款产品获批上市，2个品种在中国国家药品监督管理局审评 中，4个新药分子进入3期或关键性临床研究，另外约15个新药品种已进入临床研究。2025年是本公司迈 入双轮驱动和全球创新发展新时期的重要一年，将朝着"成为国际一流的生物制药公司"的愿景稳步迈 进。 智通财经APP讯，信达生物(01801)公布，于2025年上半年，公司共取得总产品收入超人民币52亿元，同 比保持35%以上的强劲增长;其中2025年第二季度总产品收入超过人民币27亿元，同比增长超过 30%。 该季度的持续增长得益于肿瘤和综合管线双轮驱动共同发力：1)肿瘤治疗领域的领导品牌和产品组合强 大，主要产品保持优异增长，新产品收入贡献持续提升;及2)综合产品线潜力逐渐释放，贡献增长新驱 动力：信必乐® (托莱西单抗注射液)和信必敏® (替妥尤单抗N01注射液)市场营销和渠道准入工作顺利 推进，产品持续放量。于本季度末，全球首个胰高血糖素╱胰高血糖素样肽-1 (GCG/ GLP-1)双受体激 动药物信尔美® (玛仕度肽注射液 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 （於開曼群島註冊成立的有限公司） 本公告所載財務資料乃根據本集團內部管理記錄編製，未經外聘核數師審核或審 閱，因此，有關資料僅供投資者參考。由於收集及編製有關資料過程中出現的各 種不確定性，有關資料可能有別於本公司將刊發經審核或未經審核綜合財務報表 所披露的資料（包括但不限於年度或半年度公佈的資料）。本公告並不構成亦不應 詮釋為購買或出售本集團任何證券或金融工具的要約或招攬。 （股份代號：1801） 內幕消息公告－2025年第二季度產品收入的最新消息 本公告由信達生物製藥（「本公司」，連同其附屬公司統稱「本集團」）根據香港聯合 交易所有限公司證券上市規則（「上市規則」）第13.09條及香港法例第571章證券及 期貨條例第XIVA部作出。 於2025年上半年，本公司共取得總產品收入超人民幣52億元，同比保持35%以上 的強勁增長；其中2025年第二季度總產品收入超過人民幣27億元，同比增長超過 30%。該 ...

Group 1 - The core index, the China 280 Index, increased by 0.58% to 7197.66 points with a trading volume of 207.38 billion [1] - The China 280 Index has risen 6.43% in the past month, 12.99% in the last three months, and 11.95% year-to-date [1] - The index is composed of various sub-indices, including the China 120 Index, China A80 Index, and the Hong Kong Mainland Index, reflecting the overall performance of large and mid-cap securities listed in Shanghai, Shenzhen, and Hong Kong [1] Group 2 - The top ten holdings of the China 280 Index include Guotai Junan (1.86%), Pop Mart (1.66%), and Zhongji Xuchuang (1.52%) [1] - The market capitalization distribution shows that the Shanghai Stock Exchange accounts for 44.77%, the Hong Kong Stock Exchange for 28.45%, and the Shenzhen Stock Exchange for 26.78% [2] - Sector allocations within the index include Financials (18.07%), Information Technology (17.54%), and Industrials (16.36%) [2]

Core Viewpoint - Out-licensing has become one of the most important driving forces in the domestic biopharmaceutical industry this year, with Innovent Biologics (01801) being identified as the most capable beneficiary among the companies covered by Morgan Stanley [1] Group 1: Company Analysis - Morgan Stanley raised the target price for Innovent Biologics from HKD 90 to HKD 109 and assigned an "Overweight" rating, designating it as an industry favorite [1] - Innovent Biologics has a strong product pipeline covering oncology, cardiovascular, autoimmune, and ophthalmology, creating a diversified portfolio of early and late-stage assets [1] - The firm has increased its forecast for potential licensing revenue as a percentage of total revenue to 5% to 7%, which is expected to enhance gross margin due to favorable sales mix [1] Group 2: Market Outlook - The valuation of early-stage assets has been raised by 43% due to increasing market recognition of the company's R&D capabilities [1]